{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-062490","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.494240+00:00","generated_at":"2026-05-16T01:14:57.457320+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share","bullets":["Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.","Funds will support launch readiness, medical affairs, pre-commercialization for CAN-2409 in early localized prostate cancer and phase 3 trial in NSCLC.","Underwriters granted 30-day option to purchase up to 2,752,293 additional shares at same price.","Offering expected to close Feb 23, 2026; Citigroup, Cantor, Stifel are joint bookrunners.","Pro forma cash runway extended into Q1 2028 based on base net proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-062490","json":"https://secwatch.observer/filing/0001193125-26-062490.json","markdown":"https://secwatch.observer/filing/0001193125-26-062490.md","text":"https://secwatch.observer/filing/0001193125-26-062490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526062490/0001193125-26-062490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526062490/d113082d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:14:57.457320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cab79ad6052b8997aadeea9a0da99bcb9eba9de3","claim":"Candel Therapeutics, Inc. entered into Underwriting Agreement with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated valued at approximately $93.5 million (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 18,348,624 shares (the “Firm Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), at a price to the public of $5.45 per share (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526062490/0001193125-26-062490-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated"},{"label":"Value","value":"approximately $93.5 million"},{"label":"Effective","value":"2026-02-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}